TPAO Clinical Manual
🇚🇊 TOUCHSTONE IGOEE • TPAO HANDBOOK

Ocular Therapeutics & Prescribing Clinical Manual

Complete Canadian drug monographs, dosage protocols, contraindications, steroid tapering matrices, emergency algorithms, and board-level case simulators.

00. TPAO Exam Blueprint & Core Competencies

OVERVIEW

The Therapeutics Prescribing Assessment for Optometry (TPAO) is a 98-question written multiple-choice examination administered by the Touchstone Institute. It evaluates your competence to safely prescribe, monitor, and adjust drug therapies currently authorized for optometrists in Canada.

DOMAIN 1 (40%) Diagnosis & Selection

Selecting 1st-line drug therapy vs. alternatives based on clinical presentation.

DOMAIN 2 (35%) Pharmacology & Safety

Mechanisms, adverse effects, systemic contraindications, and drug interactions.

DOMAIN 3 (25%) Monitoring & Tapering

Follow-up intervals, treatment response, steroid tapering, and emergency triage.

01. Glaucoma & Hypotensive Drug Classes

CH 01
PROSTAGLANDIN ANALOG (PGA)

Latanoprost 0.005%, Travoprost 0.004%, Bimatoprost 0.01%/0.03%

1st-Line Choice (25–35% IOP Drop)
Mechanism of Action:

Selective FP prostanoid receptor agonist that increases uveoscleral outflow (unconventional pathway).

Dosing & Administration:

1 drop QHS (at bedtime).

Morning dosing is less effective due to diurnal receptor down-regulation.

Adverse Effects & Cautions:

Iris color darkening (permanent), eyelash hypertrichosis, periorbital fat atrophy (PAP), CME. Avoid in active uveitis & history of epithelial HSV.

BETA-BLOCKER

Timolol Maleate 0.25% / 0.5% (Timoptic, Timoptic-XE)

20–25% IOP Drop
Mechanism of Action:

Non-selective $\beta_1$ and $\beta_2$ adrenergic antagonist that decreases aqueous humor production by the ciliary epithelium.

Dosing & Administration:

1 drop QAM (morning) or BID.

Little nighttime pressure efficacy because aqueous production naturally drops during sleep.

Absolute Contraindications:

Asthma, severe COPD, sinus bradycardia (<50 bpm), 2nd/3rd degree heart block, decompensated CHF.

ALPHA-2 AGONIST

Brimonidine Tartrate 0.1% / 0.15% (Alphagan P)

Dual Mechanism (20–25% IOP Drop)
Mechanism of Action:

Dual action: Decreases aqueous production AND increases uveoscleral outflow.

Dosing:

1 drop TID (monotherapy) or BID (adjunct).

Key Board Pearl:

CONTRAINDICATED in children under 2 years / <20 kg (crosses blood-brain barrier causing CNS depression, bradycardia, hypotension, apnea).

CARBONIC ANHYDRASE INHIBITOR

Dorzolamide 2% (Trusopt), Brinzolamide 1% (Azopt), Acetazolamide (Diamox)

15–20% IOP Drop
Mechanism:

Inhibits carbonic anhydrase II in non-pigmented ciliary epithelium, decreasing bicarbonate production and aqueous secretion.

Dosing:

Topical: TID (mono) or BID (adjunct).
Oral Diamox: 250mg tab or 500mg sequel.

Contraindications:

Sulfa allergy, severe renal disease (GFR <30), hepatic impairment, hypokalemia, aplastic anemia (oral).

02. Anti-Infectives & Microbial Keratitis

CH 02

Step-by-Step Microbial Keratitis Management Algorithm

1. Non-Sight-Threatening (Small <1.5mm, Peripheral, No AC Reaction)

• Drug: Moxifloxacin 0.5% (Vigamox) or Besifloxacin 0.6% (Besivance) 1 drop every 1 to 2 hours while awake.
• Adjunct: Cyclopentolate 1% BID (relieves ciliary spasm pain).
• Follow-up: Mandatory in 24 hours.

2. Severe / Sight-Threatening (Central >2mm, Deep Stromal Infiltrate, Hypopyon/AC Reaction)

• Loading Regimen: 1 drop every 15 minutes for the first 2 hours, then 1 drop every 1 hour around the clock (including through the night).
• Choice: Fortified Tobramycin (15 mg/mL) alternating with Fortified Cefazolin (50 mg/mL) OR 4th Gen Fluoroquinolone.
• Golden Rule: NO STEROIDS until re-epithelialization is established and organism is controlled (minimum 48–72h).

03. Topical Corticosteroids & Step-Down Tapering

CH 03

Corticosteroids are essential for treating sterile inflammatory ocular conditions (Anterior Uveitis, Episcleritis, Stromal Keratitis). Sudden cessation causes rebound inflammation. Always taper gradually based on anterior chamber cell resolution.

Prednisolone Acetate 1% (Pred Forte)

• Ketone formulation, high penetration.

• Shake suspension well before instillation.

• Uveitis Regimen: Q1h or Q2h initially until AC cells drop to <1+, then taper weekly: QID $\rightarrow$ TID $\rightarrow$ BID $\rightarrow$ Daily $\rightarrow$ Stop.

Loteprednol Etabonate 0.5% (Lotemax)

• Ester-based "soft steroid".

• Rapidly converted into inactive metabolites by esterases in the anterior chamber.

• Clinical Value: Lowest risk of intraocular pressure elevation (ideal for steroid responders).

04. Topical NSAIDs & Anti-Allergy Formulations

CH 04
TOPICAL NSAIDS

Ketorolac 0.4%/0.5% (Acular), Nepafenac 0.1%/0.3% (Nevanac/Ilevro), Bromfenac 0.07% (Prolensa)

Inhibits cyclooxygenase (COX-1 & COX-2) preventing prostaglandin synthesis.

• Primary Indications: Post-cataract surgery inflammation, prevention/treatment of Cystoid Macular Edema (CME), refractive surgery pain.

⚠ Warning: Risk of corneal melting in compromised/neurotrophic corneas.

DUAL-ACTING ANTI-ALLERGICS

Olopatadine 0.1%/0.2%/0.7% (Patanol/Pataday/Pazeo), Alcaftadine 0.25% (Lastacaft), Ketotifen 0.025% (Zaditor)

Dual action: Histamine $H_1$ receptor antagonist + Mast cell stabilizer.

• Primary Indication: Allergic conjunctivitis itching and redness.

• Dosing: Olopatadine 0.2% is 1 drop once daily (QD); Olopatadine 0.1% is 1 drop BID.

05. Ocular Antivirals: HSV & HZO Protocols

CH 05
Condition Clinical Hallmark First-Line Treatment Contraindications & Cautions
HSV Epithelial Keratitis True branching dendrites with terminal end-bulbs, reduced corneal sensation. Topical: Ganciclovir 0.15% gel (Zirgan) 5x/day until healed, then TID x 7d.
Oral: Valacyclovir 500mg TID x 7–10d (or Acyclovir 400mg 5x/day).
NO topical steroids during epithelial replication phase (causes geographic ulcers).
Herpes Zoster Ophthalmicus (HZO) Dermatomal CN V1 vesicular rash respecting midline, Hutchinson's sign on nasal tip. Oral Valacyclovir: 1000mg TID x 7 days (or Acyclovir 800mg 5x/day x 7d). Must start within 72h. Dose reduction required in renal impairment. Monitor for neuro-ophthalmic complications.

06. Oral Systemic Antibiotics in Optometry

CH 06
PRESEPTAL CELLULITIS / INTERNAL HORDEOLUM

Cephalexin (Keflex) 500mg BID/QID or Amoxicillin-Clavulanate (Augmentin) 875mg BID

Gram-positive coverage targeting Staphylococcus aureus and Streptococcus pneumoniae.

• Dosing duration: 7 to 10 days.

• In penicillin/cephalosporin allergy: Doxycycline 100mg BID or Trimethoprim-Sulfamethoxazole (Bactrim DS) 1 tab BID.

MGD / OCULAR ROSACEA / CHALAZION

Doxycycline 50mg–100mg Daily / BID

Sub-antimicrobial dose provides matrix metalloproteinase (MMP-9) inhibition and anti-inflammatory action.

⚠ Contraindicated in pregnancy, nursing mothers, and children <8 years (causes tooth discoloration & bone growth stunting).

07. Acute Ocular Emergencies Protocols

CH 07
CRISIS PROTOCOL: ACUTE ANGLE-CLOSURE GLAUCOMA STAT IN-OFFICE
STEP 1 (Topical Aqueous Drops)

• Timolol 0.5% (1 drop)

• Apraclonidine 1% (1 drop)

• Dorzolamide 2% (1 drop)

STEP 2 (Systemic CAI)

• Oral Acetazolamide (Diamox) 500mg STAT (two 250mg tabs)

Verify no sulfa allergy.

STEP 3 (Miosis Induction)

• Recheck IOP in 30–45 min.

Instill Pilocarpine 1–2% once IOP drops <40 mmHg (ischemic sphincter will not constrict at >45 mmHg).

STEP 4 (Definitive Referral)

• Immediate referral for bilateral Laser Peripheral Iridotomy (LPI).

08. Canadian Prescription Writing Templates

CH 08
Rx: Glaucoma (Latanoprost)
Rx: Latanoprost 0.005% ophthalmic solution
Sig: Instill 1 drop into both eyes (OU) once daily at bedtime (QHS).
Mitte: 1 x 2.5 mL bottle
Refills: 3 (three)
Rx: Acute Uveitis (Pred Forte)
Rx: Prednisolone Acetate 1% suspension (Pred Forte)
Sig: Shake well. Instill 1 drop into right eye (OD) every 1 hour while awake for 3 days, then every 2 hours until follow-up in 4 days.
Mitte: 1 x 10 mL bottle
Refills: 0 (zero)

09. Interactive Steroid Taper Generator

CALCULATOR

10. TPAO Practice Case Simulator

EXAM MODE
CASE 1 OF 3 GLAUCOMA & CONTRAINDICATIONS

A 67-year-old male with newly diagnosed Primary Open-Angle Glaucoma has a medical history of moderate COPD and sinus bradycardia (HR 50 bpm). Which of the following is the MOST appropriate first-line pressure-lowering agent?

CASE 2 OF 3 CORNEAL ULCER LOADING

A 24-year-old soft contact lens wearer presents with a 2.5mm central bacterial corneal ulcer with 2+ anterior chamber cells. What is the MOST appropriate initial topical loading regimen?